Map Pharmaceuticals (NASDAQ:MAPP) reported a Q4 loss of $0.45 per share, missing estimates for a loss of $0.29 per share.The company reported Q4 revenues of $837,000 vs. estimates of $3.65 million. The figure may not be comparable.The company intends to restate interim financial statements for timing of revenue recognition for Allergan milestone payment.MAP Pharmaceuticals (NASDAQ:MAPP) has potential upside of 49.8% based on a current price of $16.19 and an average consensus analyst price target of $24.25.
